Compare New York Times Co (NYT) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
New York Times Co vs Regeneron Pharmaceuticals Inc — how do they compare? New York Times Co trades at $66.6 (market cap $10.74B), while Regeneron Pharmaceuticals Inc trades at $740.01 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 7.1× New York Times Co's market cap, and New York Times Co pays the higher dividend (1.38%). Which is the better fit depends on your goals — on Pluang, investors hold New York Times Co for 81 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| NYT | REGN | |
|---|---|---|
Market Cap | $10.74B | $76.14B |
Volume | 2,096,352 | 500,239 |
Sector | Media | Health |
52-Week High | $85.86 | $852.03 |
52-Week Low | $54.66 | $557.73 |
Typical Hold Time | 81 Days | 107 Days |
Enterprise Value | $10.14B | $70.85B |
Dividend Yield | 1.38% | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The New York Times Company (NYT) trades at $64.90, up 1.3% with strong fundamentals including 12.17% net margin and consistent earnings beats. Technical indicators show bearish momentum with support at $62-64 and resistance at $65-67. Recent news highlights dividend declaration and ongoing AI copyright litigation.
Outlook remains positive with 35% analyst buy ratings and $84 consensus target, though legal risks and technical bearish signals warrant caution. Revenue growth trajectory and strong profitability support long-term value despite near-term headwinds.
Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.
The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
